- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.04. | PEGBIO CO-B (02565): 2025 ANNUAL REPORT | - | HKEx | ||
| 28.04. | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT NOTICE ABOUT VOLUNTARY EXTENSION OF LOCK-UP PERIOD GIVEN BY A CORNERSTONE INVESTOR | - | HKEx | ||
| 09.04. | PEGBIO CO-B-50 (02565): INSIDE INFORMATION ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION APPLICATION BY THE COMPANY | - | HKEx | ||
| PEGBIO Aktie jetzt für 0€ handeln | |||||
| 02.04. | PEGBIO CO-B-50 (02565): VOLUNTARY ANNOUNCEMENT RESEARCH ABSTRACT RELATED TO CR059 ACCEPTED BY THE 2026 SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION ... | - | HKEx | ||
| 01.04. | PEGBIO CO-B-50 (02565): CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 ... | - | HKEx | ||
| 23.03. | PEGBIO CO-B (02565): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025 | 2 | HKEx | ||
| 16.03. | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT PEGBIO ENTERS INTO EXCLUSIVE COMMERCIALIZATION COLLABORATION WITH TENRY PHARMACEUTICAL FOR PAIDAKANG IN MAINLAND ... | 2 | HKEx | ||
| 11.03. | PEGBIO CO-B (02565): DATE OF BOARD MEETING | 3 | HKEx | ||
| 10.03. | PEGBIO CO-B (02565): CHANGE IN BOARD LOT SIZE | - | HKEx | ||
| 06.03. | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT PEGBIO'S NEXT-GENERATION GLP-1 (CR059) COMPLETES FIRST-IN-HUMAN TRIAL WITH ONE-MONTH CLINICAL OBSERVATIONS ... | 3 | HKEx | ||
| 23.12.25 | PEGBIO CO-B (02565): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 22.12.25 | PEGBIO CO-B (02565): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 22.12.25 | PEGBIO CO-B (02565): COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE | - | HKEx | ||
| 15.12.25 | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT NOTICE ABOUT VOLUNTARY EXTENSION OF LOCK-UP PERIOD GIVEN BY A CORNERSTONE INVESTOR | 1 | HKEx | ||
| 28.11.25 | PEGBIO CO-B (02565): INSIDE INFORMATION ANNOUNCEMENT FILING WITH THE CSRC REGARDING THE APPLICATION FOR THE PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION | 2 | HKEx | ||
| 26.11.25 | PEGBIO CO-B (02565): VOLUNTARY ANNOUNCEMENT NOTICE ABOUT VOLUNTARY EXTENSION OF LOCK-UP PERIOD GIVEN BY A CORNERSTONE INVESTOR | - | HKEx |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,350 | -1,56 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Qiagen nach endgültigen Quartalszahlen auf "Equal Weight" mit einem Kursziel von 38 US-Dollar belassen. Analyst... ► Artikel lesen | |
| EVOTEC | 4,540 | -10,63 % | Mit guten Konzepten und Entspannung im Nahost-Konflikt voran! MustGrow, K+S, Evotec und Novo Nordisk im Fokus | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Was für eine Nachricht: Einigung zwischen USA und dem Iran - Märkte plus 2 % in nur 1 Minute! So schnell kann es gehen. Für Investoren... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,220 | 0,00 % | H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) | ||
| TARSUS PHARMACEUTICALS | 64,66 | 0,00 % | Tarsus reiterates 2026 net product sales guidance of $670M-$700M as XDEMVY posts $145.4M in Q1 sales | ||
| BICARA THERAPEUTICS | 20,990 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow-up... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,690 | 0,00 % | Arcutis Q1 2026: Umsatz steigt um 65 %, doch Expansionskosten führen zu höheren Verlusten | ||
| PRAXIS PRECISION MEDICINES | 346,46 | -0,11 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,330 | 0,00 % | Allogene Therapeutics Q1 2026 Earnings Call Transcript | ||
| TANGO THERAPEUTICS | 25,510 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | ||
| C4 THERAPEUTICS | 3,660 | -0,54 % | C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab... ► Artikel lesen | |
| BIONTECH | 78,95 | +0,25 % | Alarm bei BioNTech! Milliarden bei Hensoldt! Kaufchance bei North Arrow Minerals! | "Erst kaufen, dann killen", so reagierte Tübingens Oberbürgermeister Boris Palmer auf die geplanten Standortschließungen von BioNTech. Denn in diesem Rahmen sollen praktisch alle Standorte der erst... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 117,82 | -0,11 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy |
Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| BIOVENTUS | 10,400 | 0,00 % | Bioventus, Inc.: Bioventus Reports First Quarter Financial Results | Q1 reported revenue of $132.1 million increased 7%First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted shareNon-GAAP earnings* of $0.15... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 26,860 | 0,00 % | Mineralys outlines lorundrostat U.S. launch plans ahead of December 22, 2026 PDUFA | ||
| ERASCA | 10,450 | -0,10 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen |
PEGBIO CO LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PEGBIO CO LTD finden Sie auf Wallstreet Online.